Merck & Co. Inc. (MRK): Price and Financial Metrics
GET POWR RATINGS... FREE!
MRK POWR Grades
- MRK scores best on the Growth dimension, with a Growth rank ahead of 96.78% of US stocks.
- MRK's strongest trending metric is Momentum; it's been moving down over the last 52 weeks.
- MRK ranks lowest in Momentum; there it ranks in the 13th percentile.
MRK Stock Summary
- Merck & Co Inc's market capitalization of $207,834,667,054 is ahead of 98.95% of US-listed equities.
- MRK's went public 35.93 years ago, making it older than 92.76% of listed US stocks we're tracking.
- In terms of volatility of its share price, MRK is more volatile than only 6.21% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to Merck & Co Inc, a group of peers worth examining would be ABBV, NVS, ABT, DHR, and VZ.
- MRK's SEC filings can be seen here. And to visit Merck & Co Inc's official web site, go to www.merck.com.
MRK Valuation Summary
- MRK's price/earnings ratio is 34.7; this is 4.93% lower than that of the median Healthcare stock.
- Over the past 243 months, MRK's price/sales ratio has gone up 0.7.
- Over the past 243 months, MRK's price/sales ratio has gone up 0.7.
Below are key valuation metrics over time for MRK.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| MRK | 2021-08-31 | 4.0 | 5.8 | 34.7 | 30.5 |
| MRK | 2021-08-30 | 4.0 | 5.8 | 34.8 | 30.5 |
| MRK | 2021-08-27 | 4.0 | 5.8 | 34.7 | 30.5 |
| MRK | 2021-08-26 | 4.0 | 5.8 | 34.8 | 30.6 |
| MRK | 2021-08-25 | 4.0 | 5.9 | 35.0 | 30.7 |
| MRK | 2021-08-24 | 4.1 | 5.9 | 35.3 | 31.0 |
MRK Growth Metrics
- The year over year net cashflow from operations growth rate now stands at -11.51%.
- Its 2 year price growth rate is now at 35.87%.
- Its year over year cash and equivalents growth rate is now at -5.98%.
The table below shows MRK's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-06-30 | 48,548 | 10,460 | 5,571 |
| 2021-03-31 | 48,018 | 11,337 | 7,028 |
| 2020-12-31 | 47,994 | 10,253 | 7,067 |
| 2020-09-30 | 47,348 | 11,041 | 11,518 |
| 2020-06-30 | 47,194 | 13,094 | 10,478 |
| 2020-03-31 | 48,082 | 12,811 | 10,146 |
MRK's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- MRK has a Quality Grade of B, ranking ahead of 77.57% of graded US stocks.
- MRK's asset turnover comes in at 0.535 -- ranking 75th of 682 Pharmaceutical Products stocks.
- XTNT, ACOR, and BDSI are the stocks whose asset turnover ratios are most correlated with MRK.
The table below shows MRK's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.535 | 0.675 | 0.129 |
| 2021-03-31 | 0.529 | 0.670 | 0.158 |
| 2020-12-31 | 0.538 | 0.677 | 0.171 |
| 2020-09-30 | 0.542 | 0.712 | 0.276 |
| 2020-06-30 | 0.550 | 0.701 | 0.260 |
| 2020-03-31 | 0.571 | 0.701 | 0.256 |
MRK Price Target
For more insight on analysts targets of MRK, see our MRK price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $93.38 | Average Broker Recommendation | 1.52 (Moderate Buy) |
MRK Stock Price Chart Interactive Chart >
MRK Price/Volume Stats
| Current price | $74.89 | 52-week high | $91.40 |
| Prev. close | $79.16 | 52-week low | $70.89 |
| Day low | $74.00 | Volume | 34,183,287 |
| Day high | $77.50 | Avg. volume | 12,535,506 |
| 50-day MA | $80.68 | Dividend yield | 3.28% |
| 200-day MA | $77.44 | Market Cap | 189.17B |
Merck & Co. Inc. (MRK) Company Bio
Merck & Co., Inc., d.b.a. Merck Sharp & Dohme (MSD) outside the United States and Canada, is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668. Merck & Co. was established as an American affiliate in 1891.(Source:Wikipedia)
Latest MRK News From Around the Web
Below are the latest news stories about Merck & Co Inc that investors may wish to consider to help them evaluate MRK as an investment opportunity.
Merck & Company (MRK) Gets a Buy Rating from Mizuho SecuritiesIn a report released today, Mara Goldstein from Mizuho Securities maintained a Buy rating on Merck & Company (MRK – Research Report), with a price target of $100.00. The company's shares closed last Wednesday at $82.28. According to TipRanks.com, Goldstein is a 4-star analyst with an average return of 15.4% and a 42.9% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Adaptimmune Therapeutics, Iovance Biotherapeutics, and Corvus Pharmaceuticals. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $96.36 average price target, which is a 16.4% upside from current levels. |
Merck''s anti-COVID pill ''likely not'' to be cleared for pregnant womenMISE & Agrave; DAY WASHINGTON | The anti-COVID tablet developed by Merck is effective in the treatment of the virus, estimated the United States Medicines Agency (FDA) in a preliminary report published on Friday, however, recommending that it be excluded from use in pregnant women. The publication comes ahead of a meeting of an FDA […] The post Merck''s anti-COVID pill ''likely not'' to be cleared for pregnant women first appeared on The Bobr Times . |
FDA Experts Will Review Mercks COVID19 Pill After Panel Says Its EffectiveFederal health regulators say an experimental COVID-19 pill from Merck is effective against the virus, but they will seek input from outside experts on the risks of birth defects and other potential problems during pregnancy. The Food and Drug Administration (FDA) posted its analysis of the pill ahead of a public meeting next week where The post FDA Experts Will Review Mercks COVID19 Pill After Panel Says Its Effective appeared first on HillReporter.com . |
Mercks COVID pill shows lower efficacy in updated studyDrugmaker says final analysis of trial results showed molnupiravir showed 30 percent risk reduction. |
FDA calls Merck COVID-19 pill effective, but points to safety concernsThe Food and Drug Administration (FDA) says that while Merck''s experimental COVID-19 antiviral pill is effective, the agency has yet to determine whether the medication can be safely administered during pregnancy.The FDA said a review |
MRK Price Returns
| 1-mo | -14.95% |
| 3-mo | -0.96% |
| 6-mo | 0.45% |
| 1-year | -2.97% |
| 3-year | 3.42% |
| 5-year | 42.54% |
| YTD | -6.01% |
| 2020 | -7.20% |
| 2019 | 22.27% |
| 2018 | 39.95% |
| 2017 | -1.49% |
| 2016 | 15.05% |
MRK Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching MRK
Want to do more research on Merck & Co Inc's stock and its price? Try the links below:Merck & Co Inc (MRK) Stock Price | Nasdaq
Merck & Co Inc (MRK) Stock Quote, History and News - Yahoo Finance
Merck & Co Inc (MRK) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...